Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years’ follow-up
Loibl, S; Jassem, J; Sonnenblick, A; Parlier, D; Winer, E; Bergh, J; Gelber, RD; Restuccia, E; Im, YH; Huang, C; Dalenc, F; Calvo, I; Procter, M; Caballero, C; Clark, E; Gomez Moreno, HL; Bliss, J; Viale, G; Bines, J; Piccart, M;
Annals of Oncology | Volume 33 | Issue 9 | Page(s) 986-987 | Publication Year 2022
Impact of age on clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial.
Presentation of the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial as shown at the 2017 annual meeting of the American Society of Clinical Oncology and published in the European Journal of Cancer in 2021.
The JCO confirms the invasive disease-free survival benefit from adding pertuzumab to standard adjuvant therapy for patients with node-positive HER2-positive early breast cancer.
Breast Cancer Research and Treatment published that Adjuvant trastuzumab should be considered a safe treatment from a cardiac standpoint for most patients. Further research is needed to individualize prevention and management of trastuzumab-associated cardiotoxicity.
An article published in the New England Journal of Medicine (NEJM) reports that pertuzumab, when added to chemotherapy and trastuzumab, significantly improved the rates of invasive-disease–free survival among patients with HER2-positive early breast cancer.
An article published in The Lancet shares the results from the final analysis of the HERceptin Adjuvant (HERA) trial.
JAMA Internal Medicine reports on the investigation into participation rates, adenoma yield, performance, and adverse events of population-based colonoscopy screening in several European countries.
An article in the JCO reports that adjuvant treatment that includes lapatinib did not significantly improve Disease-Free Survival compared with trastuzmab alone and added toxicity. One year of adjuvant trastuzumab remains standard of care.
